The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
coo · pe ratio · data through Oct 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for The Cooper Companies, Inc. (COO) measures how much investors pay for each dollar of the company's trailing earnings. COO's current PE ratio of 55.69x is calculated by dividing its stock price of $67.34 by its TTM earnings per share of $1.21. +50.7% elevated vs 5Y avg 37.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-10-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%31.2x
MedianQ3 · 75%90.7x
Max
At 55.69x, COO's current P/E is higher than in 89% of its annual fiscal year readings over the past 19 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
The Cooper Companies, Inc.You COO | $13.1B | 55.69x | +81.9% | $1.21 |
 Doximity, Inc. DOCS | $3.9B | 22.23x | -27.4% | $1.05 |
 Fresenius Medical Care AG & Co. KGaA FMS | $11.8B | 12.07x | -60.6% | $1.68 |
 Hologic, Inc. HOLX | $17.0B | 26.99x | -11.8% | $2.49 |
 ICON Public Limited Company ICLR | $11.4B | 62.31x | +103.5% | $2.92 |
 Neurocrine Biosciences, Inc. NBIX | $16.5B | 29.49x | -3.7% | $4.81 |
 Summit Therapeutics Inc. SMMT | $11.5B | N/A | — | -$1.44 |
Industry Average 5 peers with valid PE | — | 30.62x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-10-31Latest FY2025 | 37.30x | $1.87 | -29.7% | |
2024-10-31 FY2024 | 53.07x | $1.97 | +1.2% | |
2023-10-31 FY2023 | 52.45x | $1.49 | +50.1% | |
2022-10-31 FY2022 | 34.94x | $1.96 | +394.5% | |
2021-10-31 FY2021 | 7.06x | $14.93 | -89.2% | |
2020-10-31 FY2020 | 65.71x | $1.21 | +113.8% | |
2019-10-31 FY2019 | 30.74x | $2.37 | -66.1% | |
2018-10-31 FY2018 | 90.66x | $0.71 | +187.8% | |
2017-10-31 FY2017 | 31.50x | $1.91 | +1.1% | |
2016-10-31 FY2016 | 31.17x | $1.41 | -14.2% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for The Cooper Companies, Inc. (COO) measures how much investors pay for each dollar of the company's trailing earnings. COO's current PE ratio of 55.69x is calculated by dividing its stock price of $67.34 by its TTM earnings per share of $1.21.
Frequently asked questions
COO pe ratio · 6 questionsCOO's current PE ratio is 55.69x as of 2026-06-08, based on a stock price of $67.34 and TTM EPS of $1.21. Data sourced from Financial Modeling Prep via COO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · The Cooper Companies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08